Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Heart transplant is a scary and serious surgery with a high cost, but for patients with heart failure it can be the only ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Kidney disease, leading to kidney failure, afflicts disproportionately more black people than white people. Thus, there is a ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

Current mortality prediction models for patients with kidney failure may introduce bias and applicability concerns in clinical practice, according to a large systematic review. “Risk prediction models ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.